Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Eastern Ontario Regional Laboratory Association (EORLA) and Roche Diagnostics join forces for seroprevalence study for SARS-CoV-2 Canada NewsWire OTTAWA, ON, Aug. 4, 2020 EORLA to use Elecsys® Anti-SARS-CoV-2 antibody test that helps determine exposition to the virus a...
Quick Take Checkmate Pharmaceuticals ( CMPI ) intends to raise $75 million from the sale of its common stock stock in an IPO, according to an amended registration statement . The company is advancing a biologic particle treatment for melanomas and head & neck squamous cell carcinomas....
As expected, the European Commission (EC) has approved Roche's ( OTCQX:RHHBY ) Rozlytrek (entrectinib) for the treatment of patients at least 12 years old with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced...
Gilead ( GILD ) - first, the bear case GILD reported Q2 results Thursday. The stock, which had begun underperforming the sector ( IBB ), dropped further, and on a weak day for biotech Friday closed down 3.9% at $69.53. After having led the sector up this year, it is now lagging IBB's to...
"Yeah, but the valuation!" hasn't gotten me very far with Danaher ( DHR ), as a combination of strong execution, healthy underlying secular market growth, and the Street's enthusiasm for exceptional acyclical (and high-margin) growth stories has pushed valuation aside as a reason not to buy....
Quick Take Checkmate Pharmaceuticals ( CMPI ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The company is a clinical stage biopharma advancing a drug treatment candidate for melanoma and head & neck cancer. CMPI has produ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic ® (cobimetinib) and Zelboraf ® (vemurafenib) for the treatment of BRAF V600 mutation-pos...
PLEASANTON, Calif. , July 30, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® prime Pre-analytical System to improve efficiency in molecular diagnostics laboratories. The system minimises repetitive manual tasks associated with process...
UCB S.A. ( OTCPK:UCBJF ) inks an agreement with Roche ( OTCQX:RHHBY ) and Genentech granting the parties exclusive global development and commercialization rights to UCB107 for the potential treatment of Alzheimer's disease (AD). More news on: UCB SA, Roche Holding AG, UCB SA, Health...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has th...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...